Author archive for Admin Isofol

  • A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

    GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (Nasdaq First North Premier Growth Market: ISOFOL), today announced that 330 patients…

    by
  • Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data

    Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM),…

    by
  • Empowered patient podcast

    Our CEO, Dr. Ulf Jungnelius, was featured on Karen Jagoda’s empowered patient podcast to discuss colorectal cancer and how our…

    by
  • Presentation and poster at ASCO Gastrointestinal Cancers Symposium

    Isofol is attending the event and will present details in the ongoing global Phase 3 AGENT clinical study (ISO-CC-007) Presentation…

    by
  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from…

    by

  • Warning: getimagesize(/home/isofolme/public_html/wp-content/uploadshttps://www.pharmasalmanac.com/hubfs/2236109/PA_logo_Hoz_2019.svg): failed to open stream: No such file or directory in /home/isofolme/public_html/wp-content/themes/joyn/includes/plugins/aq_resizer-1x.php on line 80

    Pharma’s Almanac – Round table

    Our CEO, Anders Rabbe, was featured twice in Pharma’s Almanac Q3 issue in its “Round table” segment. He discussed the…

    by
  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

    by
  • Poster ESMO 2019

    Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress GOTHENBURG,…

    by
  • Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress

    GOTHENBURG, Sweden, September 29, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced a poster presentation…

    by
  • Published abstract at ESMO

    Published abstract at ESMO “Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic…

    by